All three tenses have at least two readings, so the archetype blend applies as printed.
Of the nine metrics, 6 read as filed from the record and 3 are SI estimates, each with its reasoning, its confidence and what would change it on its card.
What did they actually do?
Has it survived what it has been through?
4 warning events since 2017; the latest 2025-05-13.
From the record
Tvardi Therapeutics, Inc.'s filings since 2017 show 4 warning events of 2 kinds: a notice about its exchange listing (8-K item 3.01, 3 times, the latest 2024-11-22); an auditor change (8-K item 4.01, the latest 2025-05-13) (its current reports).
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What has it actually done, year after year?
+73.7% a year over 9 filed years; profitable in 1 of 9.
From the record
Tvardi Therapeutics, Inc.'s 9 filed years say what it did: revenue went from $86 thousand in fiscal 2016 to $7 million in fiscal 2024, up 73.7% a year; it rose in 5 of 8 years; the deepest fall was 95% from fiscal 2020 to fiscal 2024; net income was positive in 1 of 9 of those years (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How has it treated the people who own it?
SI estimate 4.9/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Tvardi Therapeutics, Inc.'s shareholder treatment is put at 4.9 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the bottom 49% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.
What are they doing right now?
Is it financially healthy right now?
ROE -87%: lost 87¢ per shareholder dollar. Leverage 35%: owes 35¢ per asset dollar.
From the record
Return on equity: in the fiscal year ended 2025-12-31, Tvardi Therapeutics, Inc. lost about 87 cents for every dollar of shareholders' money. Leverage: it owed about 35 cents per dollar of assets, and net share issuance: its share count grew 202.3% over the year (the filed statements).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How strong is its position in its industry?
bottom 31% of 315 in its family; net margin -411.9%.
From the record
Tvardi Therapeutics, Inc.'s standing among 315 graded names in its industry family: revenue of $7 million in fiscal 2024 ranks in the bottom 36% by size; a net margin of -411.9% ranks in the bottom 39%; revenue growth of -32.3% a year over the last 3 filed years ranks in the bottom 16% (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are the people in charge doing?
SI estimate 3.8/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Tvardi Therapeutics, Inc.'s leadership is put at 3.8 of 10 with a confidence of 35 of 100, because read from one part only, officer and director changes on Form 8-K over three years, against the people in charge, which ranks in the bottom 38% of 415 in its family; the record of its people begins on 2025-04-15 (a listing, a merger or a first filing under the rules) and its chief executive and most of the people in charge have filed since then, so the record shows a floor of 1.6 years and cannot see past it; a floor under five years is not read as years in charge. A filing that carries the missing parts replaces this estimate with the filed reading.
What are they set up to do next?
How much room does it have to grow?
SI estimate 7.6/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Tvardi Therapeutics, Inc.'s room to expand is put at 7.6 of 10 with a confidence of 35 of 100, because read from one part only, cash less debt against assets, which ranks in the top 24% of 479 in its family; the record does not carry two of the four parts: cash less debt against assets, cash from operations less capital spending against revenue, gross margin, research against revenue. A filing that carries the missing parts replaces this estimate with the filed reading.
What could actually drive growth from here?
bottom 29% of 306 in its family for growth drivers.
From the record
Tvardi Therapeutics, Inc.'s growth drivers, from the filed years to fiscal 2024: revenue grew -32.3% a year over the last three filed years against 73.7% over all 9, slowing (bottom 3% of its family); the newest year grew -65.9% (bottom 11%); research spending grew -41.9% a year (bottom 7%); capital spending grew 199.3% a year (top 3%) (its annual reports). Tvardi Therapeutics, Inc. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
Did its newest year beat what its own record pointed to?
bottom 38% of 233 in its family for expectations against reality.
From the record
Tvardi Therapeutics, Inc.'s newest year against its own record: revenue of $7 million in fiscal 2024 came in 64.3% below the $20 million its prior three years' pace pointed to (bottom 14% of its family); net income of $29 million against a prior three-year average of $97 million (top 24%); a net margin of a loss larger than its revenue against losses larger than its revenue before (bottom 25%) (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made